ARDX
Ardelyx, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow +7.4% ·
net new positions +16.7%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | 0 | 123.14M | $629.29M | +7 | −7 |
| Q1 2026 | 100 | +3 | 138.17M | $826.25M | +6 | −3 |
| Q4 2025 | 95 | +1 | 146.57M | $854.46M | +1 | — |
| Q3 2025 | 18 | +1 | 90.83M | $500.46M | +1 | — |
| Q2 2025 | 14 | -2 | 85.87M | $336.62M | — | −2 |
| Q1 2025 | 13 | +1 | 41.26M | $202.59M | +2 | −1 |
| Q4 2024 | 12 | +2 | 28.08M | $142.38M | +3 | −1 |
| Q3 2024 | 9 | 0 | 14.54M | $100.22M | — | — |
| Q2 2024 | 9 | — | 13.39M | $99.20M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 11.59M | — | $58.78M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 5.51M | +0.4% | $27.94M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 5.51M | +0.4% | $27.94M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Millennium Management ✦ | 2.96M | -26.1% | $15.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 2.49M | +12.8% | $12.63M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 2.49M | +12.8% | $12.63M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 1.47M | +9499.8% | $7.45M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 1.33M | New | $6.76M | 0.0% | New | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 1.14M | +16.0% | $5.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 650.00K | New | $3.30M | 0.0% | New | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 545.25K | -11.8% | $2.76M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 545.25K | -11.8% | $2.76M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 545.25K | -11.8% | $2.76M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 162.82K | -84.8% | $826,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Marshall Wace ✦ | 114.82K | New | $582,132 | 0.0% | New | 1 | SEC ↗ |
| 16 | Wellington Management ✦ | 107.34K | -9.2% | $544,239 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Wellington Management ✦ | 107.34K | -9.2% | $544,239 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Wellington Management ✦ | 107.34K | -9.2% | $544,239 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Wellington Management ✦ | 107.34K | -9.2% | $544,239 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $6.76M | 0.0% |
| Adage Capital Partners | $3.30M | 0.0% |
| Marshall Wace | $582,132 | 0.0% |
Exited
| Gotham Asset Management | $171,595 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 235 holders, 168.96M shares, $997.54M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 15.01K sh · $57,888
Officer, Director · 15.98K sh · $61,618
Officer, Director · 8.41K sh · $32,440
Officer, Director · 19.18K sh · $73,968
Officer · 1.56K sh · $6,009
Officer · 3.49K sh · $13,445
Officer · 3.09K sh · $11,914
Officer · 2.43K sh · $9,372
Officer · 1.73K sh · $6,688
Officer · 3.10K sh · $11,972
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology